{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:19:47Z","timestamp":1788779987831,"version":"build-2803163510"},"reference-count":31,"publisher":"Touch Medical Media, Ltd.","issue":"2","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<p\/>","DOI":"10.17925\/ee.2021.17.2.84","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T12:47:30Z","timestamp":1637412450000},"page":"84","source":"Crossref","is-referenced-by-count":15,"title":["Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus"],"prefix":"10.17925","volume":"17","author":[{"given":"Luis","family":"D\u2019Marco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nephrology Department, Hospital Cl\u00ednico Universitario, Instituto de Investigaci\u00f3n Sanitaria (INCLIVA), Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Centro de Estudios Universitarios Cardenal Herrera University, Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Puchades","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nephrology Department, Hospital Cl\u00ednico Universitario, Instituto de Investigaci\u00f3n Sanitaria (INCLIVA), Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Valencia University, Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Gand\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nephrology Department, Hospital Cl\u00ednico Universitario, Instituto de Investigaci\u00f3n Sanitaria (INCLIVA), Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Forquet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nephrology Department, Hospital Cl\u00ednico Universitario, Instituto de Investigaci\u00f3n Sanitaria (INCLIVA), Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gim\u00e9nez-Civera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nephrology Department, Hospital Cl\u00ednico Universitario, Instituto de Investigaci\u00f3n Sanitaria (INCLIVA), Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayara","family":"Panizo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nephrology Department, Hospital Cl\u00ednico Universitario, Instituto de Investigaci\u00f3n Sanitaria (INCLIVA), Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Reque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nephrology Department, Hospital de Castellon, Castellon, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Juan-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nephrology Department, Hospital Cl\u00ednico Universitario, Instituto de Investigaci\u00f3n Sanitaria (INCLIVA), Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valmore","family":"Berm\u00fadez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Facultad de Ciencias de la Salud, Universidad Sim\u00f3n Bol\u00edvar, Barranquilla, Colombia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Gorriz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nephrology Department, Hospital Cl\u00ednico Universitario, Instituto de Investigaci\u00f3n Sanitaria (INCLIVA), Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Valencia University, Valencia, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Rowley WR, Bezold C, Arikan Y, et al. Diabetes 2030: Insights from yesterday, today, and future trends.\n                      Popul Health Manag\n                      . 2017;20:6\u201312.","DOI":"10.1089\/pop.2015.0181"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.\n                      Diabetes Res Clin Pract\n                      . 2019;157:107843.","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).\n                      Diabetologia\n                      . 2020;63:221-8. Correction in:\n                      Diabetologia\n                      . 2020;63:1667.","DOI":"10.1007\/s00125-020-05151-2"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.\n                      N Engl J Med\n                      . 2019;380:2295\u2013306.","DOI":"10.1056\/NEJMoa1811744"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.\n                      Eur Heart J\n                      . 2021;42:152\u201361.","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Liu LC, Schutte E, Gansevoort RT, et al. Finerenone: Third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.\n                      Expert Opin Investig Drugs\n                      . 2015;24:1123\u201335.","DOI":"10.1517\/13543784.2015.1059819"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.\n                      N Engl J Med\n                      . 2020;383:2219\u201329.","DOI":"10.1056\/NEJMoa2025845"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes.\n                      N Engl J Med\n                      . 2021. doi: 10.1056\/NEJMoa2110956.","DOI":"10.1056\/NEJMoa2110956"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Carlstr\u00f6m M. Nitric oxide signalling in kidney regulation and cardiometabolic health.\n                      Nat Rev Nephrol\n                      . 2021;17:575\u201390.","DOI":"10.1038\/s41581-021-00429-z"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Go AS, Yang J, Tan TC, et al. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus.\n                      BMC Nephrol\n                      . 2018;19:146.","DOI":"10.1186\/s12882-018-0942-1"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Jankowski J, Floege J, Fliser D, et al. Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options.\n                      Circulation\n                      . 2021;143:1157\u201372.","DOI":"10.1161\/CIRCULATIONAHA.120.050686"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.\n                      Nat Rev Nephrol\n                      . 2018;14:442\u201356.","DOI":"10.1038\/s41581-018-0018-2"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Whaley-Connell A, Sowers JR. Basic science: Pathophysiology: The cardiorenal metabolic syndrome.\n                      J Am Soc Hypertens\n                      . 2014;8:604\u20136.","DOI":"10.1016\/j.jash.2014.07.003"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes - 2020.\n                      Diabetes Care\n                      . 2020;43(Suppl. 1):S135\u201351.","DOI":"10.2337\/dc20-S011"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lee JF, Berzan E, Sridhar VS, et al. Cardiorenal protection in diabetic kidney disease.\n                      Endocrinol Metab (Seoul)\n                      . 2021;36:256\u201369.","DOI":"10.3803\/EnM.2021.987"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Ortiz A, Ferro CJ, Balafa O, et al. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.\n                      Nephrol Dial Transplant\n                      . 2021;4;gfab167. doi: 10.1093\/ndt\/gfab167.","DOI":"10.1093\/ndt\/gfab167"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Pitt B, Anker SD, B\u00f6hm M, et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): A randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease.\n                      Eur J\n                      Heart Fail\n                      . 2015;17:24\u201332.","DOI":"10.1002\/ejhf.218"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.\n                      N Engl J Med\n                      . 1999;341:709\u201317.","DOI":"10.1056\/NEJM199909023411001"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.\n                      N Engl J Med\n                      . 2003;348:1309\u201321.","DOI":"10.1056\/NEJMoa030207"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Preiss D, van Veldhuisen DJ, Sattar N, et al. Eplerenone and new-onset diabetes in patients with mild heart failure: Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).\n                      Eur J Heart Fail\n                      . 2012;14:909\u201315.","DOI":"10.1093\/eurjhf\/hfs067"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.\n                      Kidney Int\n                      . 2019;96:302\u201319.","DOI":"10.1016\/j.kint.2019.02.030"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Agarwal R, Anker SD, Bakris G, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: The role of finerenone.\n                      Nephrol Dial Transplant\n                      . 2020;gfaa294. doi: 10.1093\/ndt\/gfaa294.","DOI":"10.1093\/ndt\/gfaa294"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Ruilope LM, Tamargo J. Renin-angiotensin system blockade: Finerenone.\n                      Nephrol Ther\n                      . 2017;13(Suppl. 1):S47\u201353.","DOI":"10.1016\/j.nephro.2017.02.003"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Orena S, Maurer TS, She L, et al. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy.\n                      Front Pharmacol\n                      . 2013;4:115.","DOI":"10.3389\/fphar.2013.00115"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Huang LL, Nikolic-Paterson DJ, Han Y, et al. Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease.\n                      J Am Soc Nephrol\n                      . 2014;25:2231\u201340.","DOI":"10.1681\/ASN.2012111094"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ayuzawa N, Fujita T. The mineralocorticoid receptor in salt-sensitive hypertension and renal injury.\n                      J Am Soc Nephrol\n                      . 2021;32:279\u201389.","DOI":"10.1681\/ASN.2020071041"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Provenzano M, Puchades M, Nicola L, et al. Study design of the rotation for optimal targeting of albuminuria and treatment evaluation (ROTATE-3): A rotation study of different albuminuria lowering drugs classes to study individual drug response in diabetic and non-diabetic CKD.\n                      Nephrol Dial Transplant\n                      . 2020;35(Suppl.):1003.","DOI":"10.1093\/ndt\/gfaa142.P1003"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Pei H, Wang W, Zhao D, et al. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.\n                      Medicine (Baltimore)\n                      . 2018;97:e0254.","DOI":"10.1097\/MD.0000000000010254"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis.\n                      Clin J Am Soc Nephrol\n                      . 2009;4:542\u201351.","DOI":"10.2215\/CJN.04750908"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Gorriz JL, D'Marco L, Pastor-Gonz\u00e1lez A, et al. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia.\n                      Nephrol Dial Transplant\n                      . 2021 Jan 28:gfab003. doi: 10.1093\/ndt\/gfab003.","DOI":"10.1093\/ndt\/gfab003"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Morillas C, D'Marco L, Puchades MJ, et al. Insulin withdrawal in diabetic kidney disease: what are we waiting for?\n                      Int J Environ Res Public Health\n                      . 2021;18:5388.","DOI":"10.3390\/ijerph18105388"}],"container-title":["touchREVIEWS in Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/chronic-kidney-disease\/journal-articles\/finerenone-a-potential-treatment-for-patients-with-chronic-kidney-disease-and-type-2-diabetes-mellitus\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:59:38Z","timestamp":1764745178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchendocrinology.com\/chronic-kidney-disease\/journal-articles\/finerenone-a-potential-treatment-for-patients-with-chronic-kidney-disease-and-type-2-diabetes-mellitus\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"alternative-id":["EE.2021.17.2.84"],"URL":"https:\/\/doi.org\/10.17925\/ee.2021.17.2.84","relation":{},"ISSN":["1758-3772"],"issn-type":[{"value":"1758-3772","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}